A Company Profile of Recordati Including, for Example, 1-6 Year Forecasts for Sales Within the Drug Market.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland Ireland, Irish Eire (âr`ə) [to it are related the poetic Erin and perhaps the Latin Hibernia], island, 32,598 sq mi (84,429 sq km), second largest of the British Isles. -- Research and Markets (http://www.researchandmarkets.com/reports/c30296) has announced the addition of Recordati: Pharmavitae Profile 2005 to their offering. Introduction This analysis examines the current position and future outlook for Recordati in the ethical eth·i·cal adj. 1. Of, relating to, or dealing with ethics. 2. Being in accordance with the accepted principles of right and wrong that govern the conduct of a profession. pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. for key drugs. An interactive forecasting and analysis tool provides continually con·tin·u·al adj. 1. Recurring regularly or frequently: the continual need to pay the mortgage. 2. updated quantitative quantitative /quan·ti·ta·tive/ (kwahn´ti-ta?tiv) 1. denoting or expressing a quantity. 2. relating to the proportionate quantities or to the amount of the constituents of a compound. and qualitative qualitative /qual·i·ta·tive/ (kwahl´i-ta?tiv) pertaining to quality. Cf. quantitative. qualitative pertaining to observations of a categorical nature, e.g. breed, sex. information. Reasons to Purchase --Benchmark Recordati's performance against key rivals in the ethical pharmaceutical sector --Learn about Recordati's high potential pipeline products, with urogenital medicine emerging as a particular focus. Topics Covered CHAPTER 1 Key findings Strategic outlook Strategic recommendations Current positioning: competitive outlook 2004 Recordati's forecast revenue stream, 2005-10 Key issues facing Recordati: 2005-10 CHAPTER 2 GLOBAL COMPANY STRATEGY Introduction to Recordati Assessment of strategic position Strengths Weaknesses Opportunities Threats Strategic recommendations Therapeutic foci Evolution of R&D focus Growth strategy assessment Organic growth Partnerships/licensing Mergers and acquisitions Geographical expansion CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS Therapy area focus in 2004 Evolution of therapy area focus, 2004-10 Key growth drivers and resistors of future performance, 2005-10 Recordati's Cardiovascular franchise Marketed products R&D compounds Cardiovascular portfolio sales forecasts and forecast revenue growth Recordati's CNS franchise Marketed products CNS portfolio sales forecasts and forecast revenue growth Recordati's Gastrointestinal franchise Marketed products Gastrointestinal portfolio sales forecasts and forecast revenue growth Recordati's Infectious diseases franchise Marketed products R&D Compounds Infectious disease portfolio sales forecasts and forecast revenue growth Recordati's Autoimmune and inflammatory disorders franchise (AIID) Marketed products Autoimmune and inflammatory disease portfolio sales forecasts and forecast revenue growth Recordati's Respiratory franchise Marketed products Respiratory portfolio sales forecasts and forecast revenue growth Recordati's Urology products R&D compounds Recordati's 'Other' products Marketed products R&D compounds Generic Products CHAPTER 4 CORPORATE DEVELOPMENT Financial position, 2003-04 Revenue growth Historical assessment of Recordati's profitability, 2000-04 Cost structure 2004 operating cost ratio benchmarking Business model clustering according to 2004 cost ratios Liquidity, 2000-04 2004 growth and investment momentum Key events shaping corporate activity, 2000-04 Merger and acquisition activity Corporate alliances and deals Regulatory affairs Other business development and news CHAPTER 5 APPENDIX : SUPPORTING DATA Exchange rates LIST OF TABLES LIST OF FIGURES For more information visit http://www.researchandmarkets.com/reports/c30296 |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion